Ueda Kazutaka, Adachi Yusuke, Liu Pangyen, Fukuma Nobuaki, Takimoto Eiki
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Front Endocrinol (Lausanne). 2020 Jan 10;10:909. doi: 10.3389/fendo.2019.00909. eCollection 2019.
Premenopausal females have a lower incidence of death from cardiovascular disease (CVD) than male counterparts, supporting the notion that estrogen is protective against the development and progression of CVD. Although large-scale randomized trials of postmenopausal hormone replacement therapy failed to show cardiovascular benefits, recent ELITE study demonstrated anti-atherosclerotic benefits of exogenous estrogen depending on the initiation timing of the therapy. These results have urged us to better understand the mechanisms for actions of estrogens on CVD. Here, we review experimental and human studies, highlighting the emerging role of estrogen's non-nuclear actions linking to NO-cGMP signaling pathways.
绝经前女性心血管疾病(CVD)的死亡率低于男性,这支持了雌激素对CVD的发生和发展具有保护作用的观点。尽管绝经后激素替代疗法的大规模随机试验未能显示出心血管益处,但最近的ELITE研究表明,外源性雌激素的抗动脉粥样硬化益处取决于治疗开始的时机。这些结果促使我们更好地理解雌激素对CVD作用的机制。在此,我们回顾了实验研究和人体研究,重点强调了雌激素与NO-cGMP信号通路相关的非核作用的新作用。